Gene · 4486
Papers1,924
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 1,924
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Association of circulating gene expression signatures with stiffness following total knee arthroplasty for osteoarthritis: a pilot study. | Sci Rep | 2022 | 35879399 | PubTator, text mining | PubMed |
| Heterogeneous nuclear ribonucleoprotein A/B: an emerging group of cancer biomarkers and therapeutic targets. | Cell Death Discov | 2022 | 35879279 | PubTator, text mining | PubMed |
| Curcuminoids as Modulators of EMT in Invasive Cancers: A Review of Molecular Targets With the Contribution of Malignant Mesothelioma Studies. | Front Pharmacol | 2022 | 35873564 | PubTator, text mining | PubMed |
| Cooperative engagement and subsequent selective displacement of SR proteins define the pre-mRNA 3D structural scaffold for early spliceosome assembly. | Nucleic Acids Res | 2022 | 35871302 | PubTator, text mining | PubMed |
| Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling. | Prostate | 2022 | 35860905 | PubTator, text mining | PubMed |
| A novel risk stratification model based on the Children's Hepatic Tumours International Collaboration-Hepatoblastoma Stratification and deoxyribonucleic acid methylation analysis for hepatoblastoma. | Eur J Cancer | 2022 | 35816972 | PubTator, text mining | PubMed |
| Investigation of the Molecular Mechanisms Underlying the Antiatherogenic Actions of Kaempferol in Human THP-1 Macrophages. | Int J Mol Sci | 2022 | 35806463 | PubTator, text mining | PubMed |
| Metabolic Profile of People Living with HIV in a Treatment Hub in Manila, Philippines: A Pre- and Post-Antiretroviral Analysis. | J ASEAN Fed Endocr Soc | 2022 | 35800599 | PubTator, text mining | PubMed |
| An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer. | Cancer Drug Resist | 2022 | 35800378 | PubTator, text mining | PubMed |
| Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy. | J Hematol Oncol | 2022 | 35799213 | PubTator, text mining | PubMed |
| Reply to Qiu et al.: Hunting for leadership "causal" genes: Mission possible? | Proc Natl Acad Sci U S A | 2022 | 35787186 | PubTator, text mining | PubMed |
| Genetic variant rs9848497 up-regulates MST1R expression, thereby influencing leadership phenotypes. | Proc Natl Acad Sci U S A | 2022 | 35787185 | PubTator, text mining | PubMed |
| The hyaluronan-related genes HAS2, HYAL1-4, PH20 and HYALP1 are associated with prognosis, cell viability and spheroid formation capacity in ovarian cancer. | J Cancer Res Clin Oncol | 2022 | 35767191 | PubTator, text mining | PubMed |
| Kinome profiling of cholangiocarcinoma organoids reveals potential druggable targets that hold promise for treatment stratification. | Mol Med | 2022 | 35764936 | PubTator, text mining | PubMed |
Identification of (S)-1-(2-(2,4-difluorophenyl)-4-oxothiazolidin-3-yl)-3-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)urea as a potential anti-colorectal cancer agent. | Eur J Med Chem | 2022 | 35763868 | PubTator, text mining | PubMed |
| The SKBR3 cell-membrane proteome reveals telltales of aberrant cancer cell proliferation and targets for precision medicine applications. | Sci Rep | 2022 | 35760832 | PubTator, text mining | PubMed |
| The Potential Diagnostic Value of Immune-Related Genes in Interstitial Fibrosis and Tubular Atrophy after Kidney Transplantation. | J Immunol Res | 2022 | 35755170 | PubTator, text mining | PubMed |
| A dual-activity topoisomerase complex regulates mRNA translation and turnover. | Nucleic Acids Res | 2022 | 35748872 | PubTator, text mining | PubMed |
| NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease. | Int J Mol Sci | 2022 | 35743191 | PubTator, text mining | PubMed |
| Macrophages Are a Double-Edged Sword: Molecular Crosstalk between Tumor-Associated Macrophages and Cancer Stem Cells. | Biomolecules | 2022 | 35740975 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4486/papers?page=16